

**STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st Mar 2017**

Rs. In Lakhs

S.N	Particulars	UnAudited			Audited	
		Quarter Ended			Year Ended	
		31.03.17	31.12.16	31.03.16	31.03.17	31.03.16
1	a) Revenue from Operations	1786.36	1742.64	2286.30	8287.75	7922.73
	b) Other income	78.46	0.53	17.67	80.23	18.87
	<b>TOTAL</b>	<b>1864.82</b>	<b>1743.17</b>	<b>2303.97</b>	<b>8367.98</b>	<b>7941.60</b>
2	Expenditure:					
	a) Cost of material consumed	1525.08	1272.23	1609.94	6311.58	5667.72
	b) Purchase of stock in trade	0.01	0.00	7.99	13.73	27.16
	c) Changes in inventories of finished good, work-in-progress, stock in trade	(247.56)	(114.33)	95.84	(431.28)	172.79
	d) Excise Duty	116.77	157.58	228.04	727.9	810.64
	e) Employee benefit expenses	58.07	62.94	56.62	237.91	216.94
	f) Finance Cost	75.38	60.35	55.43	250.94	187.99
	e) Depreciations	28.51	21.36	16.36	80.68	62.62
	g) Other Expenditure	220.65	226.03	186.52	905.73	577.95
	<b>TOTAL</b>	<b>1776.91</b>	<b>1686.16</b>	<b>2256.74</b>	<b>8097.19</b>	<b>7723.81</b>
3	Profit/Loss from Operations before Exceptional and extraordinary items and tax	87.91	57.01	47.23	270.79	217.79
4	Exceptional Items	0.00	0.00	0.00	0.00	0.00
5	Profit/Loss from Operations before Extraordinary items and tax	87.91	57.01	47.23	270.79	217.79
6	Extraordinary Items	0.00	0.00	0.00	0.00	
7	Profit/Loss from Operations before tax	87.91	57.01	47.23	270.79	217.79
8	Tax Expenses					
	i) Current tax	11.32	15.07	5.77	55.40	63.52
	ii) Deferred tax	22.80	4.08	19.16	39.48	19.17
	Less: Mat Credit Entitlement	(5.01)			(5.01)	0.00
9	Net Profit/Loss for the Period	58.80	37.86	22.30	180.92	135.10
10	Paid-up Equity Share Capital (Face Value : Rs. 10)	753.05	753.05	753.05	753.05	753.05
11	Reserve excluding Revaluation Reserve (as per Balance Sheet) of Previous accounting Year	-	-	-	868.90	687.97
12	a) Earning Per Share (EPS) before Extraordinary Items					
	i) Basic EPS (*not annualised)	0.78	0.50	0.30	2.40	1.79
	ii) Diluted EPS (*not annualised)	0.78	0.50	0.30	2.40	1.79
	b) Earning Per Share (EPS) after extraordinary Items					
	i) Basic EPS (*not annualised)	0.78	0.50	0.30	2.40	1.79
	ii) Diluted EPS (*not annualised)	0.78	0.50	0.30	2.40	1.79

Rs. In Lakhs

STATEMENT OF ASSETS AND LIABILITIES		
PARTICULARS	31.03.2017	31.03.2016
<b>SHARE HOLDERS FUND</b>		
Share Capital	753.05	753.05
Reserve & Surplus	868.90	687.97
<b>Non Current Liabilities</b>		
Deferred Tax Liabilities (Net)	120.43	80.96
Long Term Borrowings	438.57	391.74
Long Term Provisions	39.12	33.48
<b>Current Liabilities</b>		
short Term Borrowings	1133.35	1155.87
Trade Payables	2005.97	1735.67
Other current liabilities	201.58	213.27
Short Term Provisions	9.05	2.45
<b>TOTAL</b>	<b>5570.02</b>	<b>5054.46</b>
<b>Non Current Assets</b>		
Fixed Assets		
Tangible Assets	1276.97	872.62
Capital Work in Progress	11.53	119.65
Non Current Investments	0.01	0.01
Long Term Loans & Advances	18.67	22.47
<b>Current Assets</b>		
Inventories	1132.42	1074.49
Trade Receivables	2417.10	2454.63
Cash & Bank Balances	88.28	65.04
Short Term Loans & Advances	622.70	443.79
Other Current Assets	2.34	1.76
<b>TOTAL</b>	<b>5570.02</b>	<b>5054.46</b>

Notes:

- The above audited financial results were reviewed by Audit Committee and approved by Board of Directors in its meeting held on 30th May, 2017.
- The Company operated in only one segment viz., APIs (Bulk Drug) & intermediates manufacturing.
- The figures of last quarter ended 31<sup>st</sup> March, 2017 are the balancing figures between audited figures in respect of the full financial year ended 31<sup>st</sup> March, 2017 and the published year to date figures up to the third quarter of the current financial year.
- As per the circular dated July 5, 2016 issued by Securities and Exchange Board of India ("SEBI"), excise duty which had been netted off from sales, as per the format for results issued by SEBI have from the current period been disclosed as an expense. The amounts for the corresponding periods also reflect a similar change in presentation
- No investors complaint was received during the quarter & no complaint is pending at the beginning and the end of quarter.
- Previous period's/year's figures have been regrouped/rearranged wherever necessary.

Place: Secunderabad  
 Date: 30/05/2017

for Godavari Drugs Limited

*K.K. Jain*  
 K.K. Jain  
 (Director Finance)

